(Affirm)

Affirm shares sink as the buy now, pay later giant posts surprise profit but disappointing guidance

Revenue surged in the third quarter, but the future may not be so bright.

5/9/25 1:14PM

Affirm shares were down 13% Friday afternoon after the payment installment company posted a surprise Q3 profit but gave a chillier revenue outlook.

Adjusted earnings per share came in at $0.01, swinging to a profit from last year’s loss and beating expectations for a $0.03 loss. Revenue was in line with estimates at $783 million, while gross merchandise volume (an important metric that tracks total transactions) topped forecasts, jumping 36% to $8.6 billion.

Despite the beat, investors were spooked by a cautious revenue forecast for the current quarter, with the midpoint landing below Wall Street targets. The slowdown comes as the broader US economy feels the impact of new Trump-era tariffs and cooling consumer spending, with lower-income shoppers in particular pulling back.

On the flip side, Affirm’s Gross Merchandise Volume (GMV) growth has stayed resilient, fueled in part by the company’s 0% loan offers and new users joining through Apple and Amazon.

Affirm expects Q4 GMV to land between $9.4 billion and $9.7 billion, with the midpoint of $9.55 billion topping estimates.

Despite Friday’s sell-off, Affirm shares are still up nearly 35% year to date.

Matt Phillips3h

With their recent surge, Intel shares just hit their highest level since the dot-com era

Intel’s surge of nearly 60% this month has the iconic American chipmaker’s stock price approaching levels last seen during the dot-com era. Bloomberg noted that shares just touched their highest intraday level since the turn of the century:

“The stock rose as much as 1.5% to $69.55, topping a peak it hit on Jan. 24, 2020. The shares are up 90% this year, after soaring 84% in 2025. Intel is now roughly 8% from its all-time closing high of $74.88, established on Aug. 31, 2000.”

That’s just the most recent late-’90s-era throwback we’ve been seeing in tech shares lately. Oracle is currently pacing for its best week since late 1999.

What’s even more remarkable, however, is that Intel’s forward price-to-earnings ratio today dwarfs the premiums the market was putting on the stock during the nuttiness of the dot-com mania.

That reflects the fact that the recent run-up in Intel shares is, essentially, giving the chip giant credit for a massive turnaround that hasn’t actually happened yet.

One also might wonder if the fact that Intel is partially owned by the US government means it’s more attractive — and therefore worth a higher premium — than other chipmakers without the state imprimatur.

Still, kind of startling.

Jake Paul v Anthony Joshua - Fighter Showcase & Open Workout

Netflix sinks following disappointing outlook as investors wait for more ad growth

Netflix shares are down more than 10% on Friday morning.

Max Knoblauch4h

J. Edward Moreno4h

Eli Lilly’s GLP-1 pill hit nearly 1,400 prescriptions in first week

Eli Lilly rose after preliminary numbers cited by Wall Street analysts showed strong uptake of its new weight-loss pill.

The FDA approved Foundayo on April 1 and shipments began on April 9. In its first week, roughly 1,400 US prescriptions were written for the drug, according to IQVIA data cited by Deustche Bank analysts in a Friday note.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

Eli Lilly makes the world’s bestselling drug. Can it keep the party going?

Claire Yubin Oh5h

Critical Metals jumps after Greenland’s government approves CRML to take majority control of the Tanbreez mining project

Critical Metals is up more than 25% in premarket trading on Friday after the critical mining company announced that it now owns 92.5% of the Tanbreez rare earth deposit following an approval from the government of Greenland.

With that latest government support, Critical Minerals added an additional 50.5% stake to its ownership, reportedly acquired from Rimbal Pty Ltd, per Bloomberg News. With access to eight heavy rare earth elements often used in consumer electronics and defense, the site is one of the world’s largest undeveloped rare earth deposits and a key source of rare earth supply outside of China, according to the company.

In Critical Metals’ press release, Chairman Tony Sage commented that the approval “removes the most significant structural overhang on the project and provides the clarity to advance Tanbreez to production with confidence,” especially as Tanbreez’s location offers a significant logistical advantage through its year-round direct shipping access, compared to rival projects.

With 92.5% of the project now vested in Critical Metals Corp., and the remainder owned by European Lithium Ltd., CRML now has full control of the project and is seeking to accelerate development there, with plans for a new international airport and a “150-tonne bulk sample program,” which is slated for June 2026.

Matt Phillips

Oil plunges and stocks jump as Trump and Iranian foreign minister say Strait of Hormuz is open, though uncertainty remains

Citing Israel-Lebanon agreement, Iranian Foreign Minister Seyed Abbas Araghchi said on social media that the strait is “completely open for the remaining period of ceasefire.” President Trump confirmed the news shortly thereafter.